AttendMe Owl Logo
AttendMe
Evidence Evolution
UrologyUrology

How This Evidence Evolved

Overactive Bladder Treatment Ladder

From Anticholinergics to Neuromodulation and Combination Therapy

33.4

Timeline

Signal

Early observations and pilot data that first suggested a new direction

Antimuscarinic drugs reduced overactive bladder symptoms but brought adverse effects. A randomized trial found that solifenacin improved urgency and other symptoms. Dry mouth occurred in 14.0% with solifenacin 5 mg, 21.3% with 10 mg, 18.6% with tolterodine, and 4.9% with placebo. Longer-term observational evidence raised a separate concern: Gray and colleagues found a dose-response association between cumulative strong anticholinergic use and dementia. These efficacy and safety findings shaped interest in other treatment options.
Proof

Landmark RCTs and pivotal trials that established the evidence base

Extension

Follow-up studies, subgroup analyses, and real-world validation

Procedural options gained comparative evidence. A placebo-controlled trial of onabotulinumtoxinA 100 U found daily incontinence changes of −2.95 versus −1.03 at week 12 (P<0.001). STEP followed selected SUmiT responders and estimated sustained improvement in 77% at 3 years. The single-arm eCoin trial reported ≥50% episode reduction in 68% at 48 weeks.
Now

Current standard of care and ongoing research directions

Overactive bladder studies support several drug and procedural options. Mirabegron and vibegron reduced incontinence and micturitions versus placebo in 12-week trials; those studies do not show that they have replaced antimuscarinics in practice. Higher cumulative strong anticholinergic exposure was associated with dementia in an older-adult cohort. In SYNERGY, mirabegron plus solifenacin improved several outcomes, but the 50-mg/5-mg combination did not show superiority over mirabegron 50 mg for the co-primary incontinence endpoint. In patients inadequately managed by anticholinergics, onabotulinumtoxinA 100 U improved symptoms versus placebo at week 12; 6.9% initiated intermittent catheterization versus 0.7% with placebo. STEP found sustained tibial nerve stimulation benefit in selected initial responders.

Landmark Trials in This Story

Chapple 20042004

Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder

Urgency episodes and incontinence episodes per 24 hours

BJU internationalRCTN=1,081
Gray 20152015Landmark

Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study

Incident dementia with cumulative anticholinergic exposure

JAMA internal medicineProspective cohortN=3,434
SCORPIO2013

Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.

Incontinence episodes per 24 h at final visit after 12 weeks: mirabegron 50 mg change −1.57 (95% CI −1.79 to −1.35) vs placebo −1.17 (−1.39 to −0.95); P<0.05

Eur UrolMulticenter randomized double-blind placebo- and tolterodine-controlled trialN=1,978
SYNERGY2017

Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).

Daily incontinence episodes at 12 weeks: solifenacin 5 mg plus mirabegron 50 mg vs mirabegron 50 mg, adjusted difference −0.23 (P=.052).

BJU internationalDouble-blind randomized 12-week trial of solifenacin plus mirabegron versus monotherapy and placebo in adults with wet overactive bladder.
EMPOWUR2020

International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR.

Change in micturitions per day at 12 weeks: vibegron −1.8 vs placebo −1.3 (P<0.001)

J UrolInternational randomized double-blind placebo- and active-controlled phase III trialN=1,518
ABC2012

Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence.

Daily urgency-incontinence reduction over 6 months: anticholinergic therapy 3.4 vs onabotulinumtoxinA 100 U 3.3 episodes (P=0.81)

N Engl J MedRandomized double-blind double-placebo-controlled trialN=249
STEP2013

Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study.

Sustained moderate or marked improvement at 3 years: estimated 77% (95% CI 64–90) of selected initial responders

The Journal of urologyProspective follow-up of selected SUmiT respondersN=50
JAMA 2016

OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial.

Daily urgency-incontinence reduction over 6 months: onabotulinumtoxinA 200 U 3.9 vs sacral neuromodulation 3.3 episodes (mean difference 0.63, 95% CI 0.13–1.14; P=0.01)

JAMAMulticenter open-label randomized trialN=381
OnabotulinumtoxinA 100 U pivotal trial2013

OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.

Daily UI change at week 12: onabotulinumtoxinA 100 U −2.95 vs placebo −1.03 episodes (P<0.001)

Eur UrolMulticenter randomized double-blind placebo-controlled phase III trial
eCoin2021

Pivotal Study of Leadless Tibial Nerve Stimulation with eCoin® for Urgency Urinary Incontinence: An Open-Label, Single Arm Trial.

At least 50% urgency-incontinence reduction at 48 weeks: 68% (95% CI 60–76) in the intention-to-treat population

J UrolProspective open-label single-arm trialN=137

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Related Evidence

Frequently Asked Questions

Are anticholinergic OAB medications associated with dementia risk?+
Gray’s prospective cohort included 3,434 adults aged ≥65 years. Higher cumulative strong anticholinergic use was associated with dementia: adjusted hazard ratio 1.54 (95% CI 1.21–1.96) for >1,095 standardized daily doses versus nonuse.
How does onabotulinumtoxinA (Botox) work for OAB and what are the risks?+
A pivotal trial gave onabotulinumtoxinA 100 U as 20 intradetrusor injections. At week 12, daily incontinence fell by 2.95 episodes versus 1.03 with placebo (P<0.001). Positive treatment response was reported by 62.8% versus 26.8%. Clean intermittent catheterization began in 6.9% versus 0.7%. These results apply to patients inadequately managed by anticholinergics.
What is the role of combination pharmacotherapy for OAB?+
SYNERGY tested solifenacin plus mirabegron against monotherapy and placebo. The 5 mg/50 mg combination improved micturition frequency and urgency incontinence versus both monotherapies. It did not show superiority over mirabegron 50 mg for total incontinence episodes (P=0.052). Urinary-retention events, dry mouth, and constipation occurred slightly more frequently with combined treatment.
How do sacral neuromodulation and tibial nerve stimulation compare?+
STEP studied tibial nerve stimulation in selected SUmiT responders: an estimated 77% maintained improvement at 3 years, with ongoing treatment.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026